The role of brimonidine tartrate gel in the treatment of rosacea

References

• WilkinJDahlMDetmarMStandard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of RosaceaJ Am Acad Dermatol200246458458711907512
   PubMed Web of Science ®Google Scholar
• ElewskiBEDraelosZDrénoBJansenTLaytonAPicardoMRosacea – global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert GroupJ Eur Acad Dermatol Venereol201125218820020586834
   PubMed Web of Science ®Google Scholar
• TanJBlume-PeytaviUOrtonneJPAn observational cross-sectional survey of rosacea: clinical associations and progression between subtypesBr J Dermatol2013169355556223600367
   PubMed Web of Science ®Google Scholar
• DrakeL webpage on the InternetPatients over 50 hardest hit with rosacea symptomsRosacea ReviewBarrington, ILNational Rosacea Society2000 Available from: http://www.rosacea.org/rr/2000/fall/article_2.phpAccessed April 16, 2014
   Google Scholar
• BlountBWPelletierALRosacea: a common, yet commonly overlooked, conditionAm Fam Physician200266343544012182520
   PubMed Web of Science ®Google Scholar
• ChosidowOCribierBEpidemiology of rosacea: updated dataAnn Dermatol Venereol2011138Suppl 3S179S18322183096
   PubMedGoogle Scholar
• AbramKSilmHMaaroosHIOonaMRisk factors associated with rosaceaJ Eur Acad Dermatol Venereol201024556557119874433
   PubMed Web of Science ®Google Scholar
• TanJBergMRosacea: current state of epidemiologyJ Am Acad Dermatol2013696 Suppl 1S27S3524229634
   PubMed Web of Science ®Google Scholar
• ShanlerSDOndoALSuccessful treatment of the erythema and flushing of rosacea using a topically applied selective a1 adrenergic receptor agonist, oxymetazoline [abstract]J Am Acad Dermatol2008582AB9 P400
   Web of Science ®Google Scholar
• DrakeL webpage on the InternetRosacea now estimated to affect at least 16 million AmericansRosacea ReviewBarrington, ILNational Rosacea Society2010 Available from: http://www.rosacea.org/rr/2010/winter/article_1.phpAccessed April 16, 2014
   Google Scholar
• WilkinJDahlMDetmarMNational Rosacea Society Expert CommitteeStandard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosaceaJ Am Acad Dermatol200450690791215153893
   PubMed Web of Science ®Google Scholar
• DrakeL webpage on the InternetResearch shows higher prevalenceRosacea ReviewBarrington, ILNational Rosacea Society2008 Available from: http://www.rosacea.org/rr/2008/fall/article_2.phpAccessed April 16, 2014
   Google Scholar
• DrakeL webpage on the InternetNew studies show high incidence of rosacea and possible new causesRosacea ReviewBarrington, ILNational Rosacea Society2008 Available from: http://www.rosacea.org/rr/2007/summer/article_1.phpAccessed April 16, 2014
   Google Scholar
• AbramKSilmHOonaMPrevalence of rosacea in an Estonian working population using a standard classificationActa Derm Venereol201090326927320526544
   PubMed Web of Science ®Google Scholar
• BergMLidénSAn epidemiological study of rosaceaActa Derm Venereol19896954194232572109
   PubMed Web of Science ®Google Scholar
• BaldwinHEDiagnosis and treatment of rosacea: state of the artJ Drugs Dermatol201211672573022648219
   PubMed Web of Science ®Google Scholar
• BaldwinHPsychosocial implications of rosaceaThe Dermatologist2012Supplement24
   Google Scholar
• DrakeL webpage on the InternetRosacea sufferers, take heart – you are not aloneRosacea ReviewBarrington, ILNational Rosacea Society1997 Available from: http://www.rosacea.org/rr/1997/winter/article_1.phpAccessed September 9, 2014
   Google Scholar
• Del RossoJQManagement of facial erythema of rosacea: what is the role of topical α-adrenergic receptor agonist therapy?J Am Acad Dermatol2013696 Suppl 1S44S5624229637
   PubMed Web of Science ®Google Scholar
• FowlerJJrJacksonMMooreAEfficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studiesJ Drugs Dermatol201312665065623839181
   PubMed Web of Science ®Google Scholar
• FowlerJJarrattMMooreABrimonidine Phase II Study GroupOnce-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studiesBr J Dermatol2012166363364122050040
   PubMed Web of Science ®Google Scholar
• MooreAKempersSMurakawaGLong-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label studyJ Drugs Dermatol2014131566124385120
   PubMed Web of Science ®Google Scholar
• IlkovitchDPomerantzRGBrimonidine effective but may lead to significant rebound erythemaJ Am Acad Dermatol2014705e109e11024742853
   PubMed Web of Science ®Google Scholar
• RouttETLevittJORebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%J Am Acad Dermatol2014702e37e3824438976
   PubMed Web of Science ®Google Scholar
• CribierBRosacea under the microscope: characteristic histological findingsJ Eur Acad Dermatol Venereol201327111336134323451732
   PubMed Web of Science ®Google Scholar
• Del RossoJQAdvances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythemaJ Clin Aesthet Dermatol201253162522468176
   PubMedGoogle Scholar
• SchwabVDSulkMSeeligerSNeurovascular and neuroimmune aspects in the pathophysiology of rosaceaJ Investig Dermatol Symp Proc20111515362
   PubMedGoogle Scholar
• Del RossoJQGalloRLKircikLThiboutotDBaldwinHECohenDWhy is rosacea considered to be an inflammatory disorder? The primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response in rosacea-prone skinJ Drugs Dermatol201211669470022648215
   PubMed Web of Science ®Google Scholar
• SteinhoffMBuddenkotteJAubertJClinical, cellular, and molecular aspects in the pathophysiology of rosaceaJ Investig Dermatol Symp Proc2011151211
   PubMedGoogle Scholar
• LaceyNDelaneySKavanaghKPowellFCMite-related bacterial antigens stimulate inflammatory cells in rosaceaBr J Dermatol2007157347448117596156
   PubMed Web of Science ®Google Scholar
• JarmudaSO’ReillyNZabaRJakubowiczOSzkaradkiewiczAKavanaghKPotential role of Demodex mites and bacteria in the induction of rosaceaJ Med Microbiol201261Pt 111504151022933353
   PubMed Web of Science ®Google Scholar
• SulkMSeeligerSAubertJDistribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosaceaJ Invest Dermatol201213241253126222189789
   PubMed Web of Science ®Google Scholar
• OdomRDahlMDoverJNational Rosacea Society Expert Committee on the Classification and Staging of RoasaceaStandard management options for rosacea, part 1: overview and broad spectrum of careCutis2009841434719743724
   PubMed Web of Science ®Google Scholar
• WolfJEJrDel RossoJQThe CLEAR trial: results of a large community-based study of metronidazole gel in rosaceaCutis2007791738017330626
   PubMed Web of Science ®Google Scholar
• ThiboutotDThieroff-EkerdtRGraupeKEfficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studiesJ Am Acad Dermatol200348683684512789172
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyAssessment Report (EMEA/CHMP/115246/2014)London, UKEuropean Medicines Agency2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002642/WC500163196.pdfAccessed April 16, 2014
   Google Scholar
• Center for Drug Evaluation and Research Policies and ProceduresNaming of Drug Product Containing Salt Drug SubstancesSilver Spring, MDUnited States Food and Drug Administration2013 Available from: http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/UCM340273.pdfAccessed April 16, 2014
   Google Scholar
• SauderDNMillerRGrattonDDanbyWGriffithsCPhillipsSBThe treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind studyJ Dermatolog Treat1997827985
   Web of Science ®Google Scholar
• Del RossoJQWebsterGFJacksonMTwo randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosaceaJ Am Acad Dermatol200756579180217367893
   PubMed Web of Science ®Google Scholar
• Soolantra® (ivermctin) [prescribing information]Forth Worth, TXGalderma Laboratories, L.P2015
   Google Scholar
• ShanlerSDOndoALSuccessful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazolineArch Dermatol2007143111369137118025359
   PubMedGoogle Scholar
• AltinyazarHCKocaRTekinNSEştürkEAdapalene vs metronidazole gel for the treatment of rosaceaInt J Dermatol200544325225515807740
   PubMed Web of Science ®Google Scholar
• GollnickHBlume-PeytaviUSzabóELSystemic isotretinoin in the treatment of rosacea—doxycycline- and placebo-controlled, randomized clinical studyJ Dtsch Dermatol Ges20108750551520337772
   PubMed Web of Science ®Google Scholar
• electronic Medicines Compendium (eMC) [webpage on the Internet]Mirvaso 3mg/g gelUxbridge, UKelectronic Medicines Compendium (eMC)2014 Available from: http://www.medicines.org.uk/emc/medicine/28682/SPC/Mirvaso+3mg+g+Gel/#PHARMACOLOGICAL_PROPSAccessed April 18, 2014
   Google Scholar
• PiwnicaDRosignoliCde MénonvilleSTVasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidineJ Dermatol Sci2014751495424802713
   PubMed Web of Science ®Google Scholar
• JacksonJMFowlerJMooreABrimonidine Phase III Study GroupImprovement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosaceaJ Drugs Dermatol201413669970424918560
   PubMed Web of Science ®Google Scholar
• FowlerJTanJJacksonJMBrimonidine Phase III Study GroupTreatment of facial erythema in patients with rosacea with topical brimonidine tartrate: correlation of patient satisfaction with standard clinical endpoints of improvement of facial erythemaJ Eur Acad Dermatol Venereol201529347448125074756
   PubMed Web of Science ®Google Scholar
• van ZuurenEJKramerSCarterBGraberMAFedorowiczZInterventions for rosaceaCochrane Database Syst Rev20113CD00326221412882
   PubMed Web of Science ®Google Scholar
• LaytonASchallerMHomeyBBrimonidine 3 mg/g gel improves patient-reported outcomes in severe facial erythema of rosaceaPoster presented at: 23rd EADV Congress Building BridgesOctober 8–12; 2014Amsterdam, the Netherlands
   Google Scholar
• Del RossoJQReply to “Allergic contact dermatitis to topical brimonidine tartrate gel 0.33% for treatment of rosacea”J Am Acad Dermatol201471483383425219709
   PubMed Web of Science ®Google Scholar
• SwansonLAWarshawEMAllergic contact dermatitis to topical brimonidine tartrate gel 0.33% for treatment of rosaceaJ Am Acad Dermatol201471483283325219708
   PubMed Web of Science ®Google Scholar